STARDaki: a consensus-based STARD extension for standardized reporting of diagnostic accuracy in acute kidney injury
Authors' conclusion
Most studies examining AKI biomarker performance fail to conform to the STARD standards for reporting, leading to poor diagnostic accuracy estimates and reduced clinical applicability and generalizability.
Study context
- Population
- Diagnostic test accuracy (DTA) studies of acute kidney injury (AKI) biomarkers published before February 2025
- Participants
- 122 DTA studies
- Outcome
- Quality and reporting of AKI biomarker DTA studies
Methodological detailsQUADAS-2 quality assessment, STARD 2015 checklist, international 17-member expert panel, modified Delphi process
- QUADAS-2 quality assessment
- STARD 2015 checklist
- International 17-member expert panel
- Modified Delphi process
Recommendations
As reported in the abstract
- DTA studies identified
- 122
- Insufficiently reported
- 15
- Remaining studies
- 107
- Reported AKI diagnosis within 48 h of sampling
- 19
- High-quality by QUADAS-2 (of these)
- 16
Further findings
Expert panel consensus (STARDaki)
- Panel agreed criteria for patient selection, reference standards and reporting of test-retest reliability to supplement STARD for AKI biomarker studies
Original publication
STARDaki: a consensus-based STARD extension for standardized reporting of diagnostic accuracy in acute kidney injury. Intensive Care Med. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →